BR112016027881A2 - antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv - Google Patents

antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv

Info

Publication number
BR112016027881A2
BR112016027881A2 BR112016027881A BR112016027881A BR112016027881A2 BR 112016027881 A2 BR112016027881 A2 BR 112016027881A2 BR 112016027881 A BR112016027881 A BR 112016027881A BR 112016027881 A BR112016027881 A BR 112016027881A BR 112016027881 A2 BR112016027881 A2 BR 112016027881A2
Authority
BR
Brazil
Prior art keywords
pdl
hpv
antagonists
treatment
negative cancers
Prior art date
Application number
BR112016027881A
Other languages
English (en)
Inventor
Shalabi Aiman
R Vasselli James
Andrew Blake-Haskins John
Steele Keith
C Rebelatto Marlon
B Robbins Paul
Ibrahim Ramy
A Stewart Ross
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of BR112016027881A2 publication Critical patent/BR112016027881A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

a invenção refere-se a métodos de tratamento de tumores negativos para o hpv compreendendo administrar uma quantidade eficaz de um antagonista da interação pdl-1/pd-1 (por exemplo, um anticorpo anti-pdl-1 ou anti-pd-1, seu fragmento ligante de antígenos).
BR112016027881A 2014-05-29 2015-05-28 antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv BR112016027881A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004731P 2014-05-29 2014-05-29
PCT/EP2015/061909 WO2015181331A1 (en) 2014-05-29 2015-05-28 Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers

Publications (1)

Publication Number Publication Date
BR112016027881A2 true BR112016027881A2 (pt) 2017-10-24

Family

ID=53276122

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016027881A BR112016027881A2 (pt) 2014-05-29 2015-05-28 antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv

Country Status (13)

Country Link
US (1) US20160031990A1 (pt)
EP (1) EP3149043A1 (pt)
JP (1) JP2017517525A (pt)
KR (1) KR20170007750A (pt)
CN (1) CN106456764A (pt)
AU (1) AU2015265859A1 (pt)
BR (1) BR112016027881A2 (pt)
CA (1) CA2949327A1 (pt)
IL (1) IL248836A0 (pt)
RU (1) RU2016151757A (pt)
SG (1) SG11201609468WA (pt)
TW (1) TW201625300A (pt)
WO (1) WO2015181331A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2376535T1 (sl) 2008-12-09 2017-07-31 F. Hoffmann-La Roche Ag Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t
RS59480B1 (sr) 2013-12-12 2019-12-31 Shanghai hengrui pharmaceutical co ltd Pd-1 antitelo, njegov fragment koji se vezuje na antigen, i njegova medicinska primena
WO2016030455A1 (en) * 2014-08-28 2016-03-03 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
KR20180040138A (ko) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
US10544224B2 (en) * 2015-07-14 2020-01-28 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor
EA201890630A1 (ru) 2015-09-01 2018-10-31 Эйдженус Инк. Антитела против pd-1 и способы их применения
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
HUE051700T2 (hu) 2016-09-14 2021-03-29 Abbvie Biotherapeutics Inc Anti-PD-1 antitestek
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
US11813279B2 (en) * 2018-12-21 2023-11-14 Aim Immunotech Inc. Compositions for cancer therapy and methods
WO2021150266A1 (en) * 2020-01-21 2021-07-29 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with il-1beta receptor signalling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599405A (en) * 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
EP3556776A1 (en) * 2012-05-31 2019-10-23 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and vegf antagonists
WO2015034519A1 (en) * 2013-09-03 2015-03-12 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
NZ718821A (en) * 2013-09-11 2022-07-01 Medimmune Ltd Anti-b7-h1 antibodies for treating tumors

Also Published As

Publication number Publication date
US20160031990A1 (en) 2016-02-04
EP3149043A1 (en) 2017-04-05
JP2017517525A (ja) 2017-06-29
CN106456764A (zh) 2017-02-22
IL248836A0 (en) 2017-01-31
CA2949327A1 (en) 2015-12-03
TW201625300A (zh) 2016-07-16
CN106456764A8 (zh) 2017-06-30
RU2016151757A (ru) 2018-07-02
KR20170007750A (ko) 2017-01-20
SG11201609468WA (en) 2016-12-29
WO2015181331A1 (en) 2015-12-03
AU2015265859A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
BR112016027881A2 (pt) antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv
CY1124033T1 (el) Δοσολογια και χορηγηση μη φουκοζυλιωμενων αντισωματων anti-cd40
BR112017000664A2 (pt) anticorpo anti-pd-1 e seu uso
EA201892294A1 (ru) Антитела и композиции против tim-3
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
MX2022002364A (es) Anticuerpos anti-pd-l1.
NZ766356A (en) Anti-pd-1 antibodies
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
EA201691488A1 (ru) Молекулы антител против pd-1 и их применения
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
EA201691556A1 (ru) Молекулы антител к tim-3 и их применение
EA201790834A1 (ru) Молекулы антител к pd-l1 и их применение
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
EA201691974A1 (ru) Антитела против ox40 и способы их применения
GEP20197034B (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
MX2022005253A (es) Anticuerpos neutralizantes de poliomavirus.
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
TW201613643A (en) Anti-CDH6 antibody drug conjugates
BR112017023579A2 (pt) combinação de um anticorpo cd30xcd16 com um antagonista de pd-1 para terapia
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
EA201991600A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR)
EA201691541A1 (ru) Новые анти-baff антитела
BR112017000714A2 (pt) indols funcionalizados e substituídos como agentes anti-câncer
BR112018067802A2 (pt) anticorpos anti-cd40 com atividade agonista melhorada

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]